RT Journal Article SR Electronic T1 Effectiveness of FDG-PET in Screening of Synchronous Cancer of Other Organs in Patients with Esophageal Cancer JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 283 OP 287 VO 34 IS 1 A1 TATSUYA MIYAZAKI A1 MAKOTO SOHDA A1 TETSUYA HIGUCHI A1 NARITAKA TANAKA A1 SHIGEMASA SUZUKI A1 MAKOTO SAKAI A1 TAKEHIKO YOKOBORI A1 MASANOBU NAKAJIMA A1 MINORU FUKUCHI A1 YOSHITO TSUSHIMA A1 HIROYUKI KATO A1 HIROYUKI KUWANO YR 2014 UL http://ar.iiarjournals.org/content/34/1/283.abstract AB Aim: We investigated the significance of pre-treatment screening by 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET) in patients with esophageal cancer. Patients and Methods: We retrospectively evaluated the clinical significance of screening in 200 patients with primary esophageal cancer using FDG-PET. Results: Out of 200 patients, 34 (17%) had synchronous multiple primary tumors; 31 patients had two types of cancers (15.5%) and three patients had three types (1.5%). The 37 second and third primary tumors were 13 stomach cancers (35.1%), 13 head and neck cancers (35.1%), seven colon (18.9%) and two lung (5.4%) cancers. When PET was performed at initial treatment for esophageal cancer, the diagnostic sensitivity of FDG-PET/Computed tomography (CT) for the second and third synchronous primary cancer were 53.8% (7/13) for the stomach; head and neck, 61.5% (8/13); colon, 42.9% (3/7); and lung, 50% (1/2), for an overall sensitivity of 54.1% (20/37 sites). Conclusion: FDG-PET/CT for patients with esophageal cancer may find both metastases from the primary esophageal cancer and other types of synchronous primary cancers.